Cytokinetics Sees Omecamtiv Potential In Certain Heart Failure Patients

The Company And Amgen Continue To Analyze GALACTIC-HF Results

Detailed data for omecamtiv mecarbil at AHA show a slim overall benefit, but Cytokinetics highlighted its effects in sicker patients and investigators emphasized the drug’s impact on reduced hospitalizations.

Autumn red leaf with cut heart in a hand - Image
Cytokinetics highlighted a greater benefit from omecamtiv mecarbil treatment in patients with lower LVEF • Source: Shutterstock

Cytokinetics, Inc. and Amgen, Inc. previously reported that the Phase III GALACTIC-HF clinical trial of heart failure drug omecamtiv mecarbil met the primary endpoint but missed a key secondary endpoint and now the full results show that the overall benefit was modest. But while Cytokinetics sees a path forward in certain patients, Amgen has not determined whether this treatment benefit is worth pursuing further.

The detailed GALACTIC-HF results were presented at the American Heart Association (AHA) virtual annual meeting on 13 November. The trial...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Clinical Trials

Pipeline Watch: Ten Approvals And Seventeen Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Obesity Treatment Could Go Global With Lilly’s Orforglipron

 

The company’s oral GLP-1 candidate has reassured on its safety at the American Diabetes Association meeting, convincing analysts it will open up new global markets.

Shigella Vaccine Pipeline And Why It Matters

 
• By 

A GSK-Bharat Biotech deal on a shigella vaccine candidate has cast a spotlight on the disease which is the second leading cause of diarrheal deaths in children below five. Scrip looks at data from Pharmaprojects, WHO and other sources to highlight why a vaccine matters and what pharma is doing

J&J’s Trispecific Antibody For Myeloma Offers Improved Safety, Potency Over Bispecifics

 

The drugmaker presented data from its Phase I study of JNJ-79635322 at ASCO and EHA showing a 100% response rate in BCMA- and GPRC5D-naïve patients.

More from R&D

ASCO: Pushing The Frontiers Of ADCs

 

Antibody-drug conjugates are a major part of the oncology pipeline, and data presented at the American Society of Clinical Oncology meeting highlight the emergence of new technologies.

Skyhawk Looks To Soar With Huntington’s Hope

 
• By 

Oral RNA splicing modulator has gone into a Phase II/III trial

Scholar Rock Shows Muscle-Building PoC In Obesity

 

The company said it intends to maintain a focus on rare neuromuscular disease with apitegromab but could consider partnering in obesity.